HIF1A and acute myeloid leukemia: TH-302 was tested in vitro and in vivo, demonstrating hypoxia-selective activity against AML by decreasing HIF-1α expression, reducing the proliferation of leukemic cells, and enhancing double-strand breaks on DNA [119,120].